1997年3月
公司成立
欧洲杯盘口成立于Novato, 加州, with an initial focus on leveraging its proprietary enzyme technology to develop therapies for genetic conditions and other diseases.
欧洲杯盘口 is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health.
自1997年成立以来, we have applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, 使用多种治疗方式.
Using our unparalleled expertise in genetics and molecular biology, we have developed eight important medicines for patients with significant unmet medical need. Our approved therapies treat achondroplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases.
As we have looked to expand our impact, our approach to cutting-edge science has remained the same. We enlist the best of the best – people with the right technical expertise and a relentless drive to solve real problems – and create an environment that empowers our teams to pursue bold, 创新的科学. Our work is deeply rooted in genetic insights, meaning we target the underlying genetic changes or proximal molecular mechanisms of disease.
With this distinctive approach to drug discovery, we’ve produced a diverse pipeline of commercial, clinical and preclinical candidates that have well-understood biology and provide an opportunity to be first-to-market or offer a substantial benefit over existing therapeutic options.
1997年3月
欧洲杯盘口成立于Novato, 加州, with an initial focus on leveraging its proprietary enzyme technology to develop therapies for genetic conditions and other diseases.
1997年12月
欧洲杯盘口 initiated its first clinical trial to evaluate a potential treatment a form of mucopolysaccharidosis.
1999年7月
欧洲杯盘口 completed its initial public offering. Since a large number of early investors were based in Europe, the company was listed on both the Swiss SWX Exchange and the Nasdaq National Market.
2005年5月
欧洲杯盘口’s 董事会 elected Jean-Jacques Bienaimé as the company’s Chief Executive Officer, 他在这个职位上待了18年多.
2006
The company established 欧洲杯盘口 Europe Ltd., headquartered in London, initially with offices in Spain, Switzerland and Italy. The company now operates in more than 70 countries around the world.
2007年12月
The 欧洲杯外围盘口 approved the first therapy for the treatment of a rare metabolic condition.
2013年2月
欧洲杯盘口 announced it had licensed the program from University College London and St. 裘德儿童研究医院. This would lead to a product approval approximately 10 years later.
2016
Expanding on its decade-long track record of supporting eligible people with rare diseases in gaining access to the company’s medicines, the 欧洲杯盘口 RareConnections program consolidated these efforts under one expanded program for people in the United States.
2018年5月
The 欧洲杯外围盘口 approved the first enzyme replacement therapy to target the underlying cause of a rare metabolic condition.
2022年8月
The European Commission approved 欧洲杯盘口’s first gene therapy for the treatment of an inheritable bleeding disorder.
2023年12月
With the retirement of longtime 欧洲杯盘口 CEO Jean-Jacques Bienaimé, Alexander Hardy was named President and Chief Executive Officer.